NutriBand (NTRB) Income from Continuing Operations (2016 - 2026)
NutriBand (NTRB) posted Income from Continuing Operations of 1241956.0 for Q2 2026, down 28.29% sequentially from 968059.0 in Q1 2026, and up 10.58% YoY from 1123150.41 in Q2 2025.
NutriBand (NTRB) Income from Continuing Operations (2016 - 2026) Analysis & Trends
NutriBand has reported Income from Continuing Operations for 11 years, with the latest figure at 1241956.0 in Q2 2026.
- Quarterly Income from Continuing Operations rose 10.58% year-over-year to 1241956.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was 8082719.0 (up 18.96% YoY) and the FY2026 annual result came in at 8229632.0, up 21.49% from the prior year.
- Income from Continuing Operations declined to 1241956.0 in Q2 2026 per NTRB's latest filing, from 968059.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 689989.0 in Q2 2022 and troughed at 5516438.0 in Q1 2025.
- A 5-year average of 1871745.44 and a median of 1534097.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations slumped 193.28% in 2025, then jumped 82.45% in 2026.
- Over 5 years, Income from Continuing Operations stood at 1075485.0 in 2022, then sank by 63.64% to 1759946.0 in 2023, then climbed by 22.58% to 1362637.0 in 2024, then slumped by 184.18% to 3872367.0 in 2025, then jumped by 67.93% to 1241956.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1241956.0, 968059.0, and 3872367.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | NutriBand | 57.74 Mn | 53.73 Mn | 196,801.00 | -1.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -1.24 Mn |
| Jan 31, 2026 | -968,059.00 |
| Oct 31, 2025 | -3.87 Mn |
| Jul 31, 2025 | -2.00 Mn |
| Apr 30, 2025 | -1.39 Mn |
| Jan 31, 2025 | -5.52 Mn |
| Oct 31, 2024 | -1.36 Mn |
| Jul 31, 2024 | -1.71 Mn |
| Apr 30, 2024 | -1.90 Mn |
| Jan 31, 2024 | -1.88 Mn |
| Oct 31, 2023 | -1.76 Mn |
| Jul 31, 2023 | -829,173.00 |
| Apr 30, 2023 | -1.02 Mn |
| Jan 31, 2023 | -1.68 Mn |
| Oct 31, 2022 | -1.08 Mn |
| Jul 31, 2022 | -1.04 Mn |
| Apr 30, 2022 | -689,989.00 |
| Jan 31, 2022 | -3.77 Mn |
| Oct 31, 2021 | -1.57 Mn |
| Jul 31, 2021 | -519,923.00 |